$LPCN SEC Filings

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.

SALT LAKE CITY, October 7, 2026 -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity Pharmaceuticals ...

Bought 9,037 shares ($19.4K) · Bought 15,970 shares ($35.6K)

Bought 12,561 shares ($27.1K)

On September 16, 2026, the Company presented at H.C. Wainwright 28th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this re...

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

SALT LAKE CITY, September 10, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at ...

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices

Granted 2,000 Stock Option (Right to Buy) ($4.22K)

No securities owned

Granted 52,781 Stock Option (Right to Buy) ($131K)

Granted 1,764 Common Stock (Right to Buy) ($3.86K)

Granted 1,764 Stock Option (Right to Buy) ($3.86K)